2020
DOI: 10.12659/msm.920310
|View full text |Cite
|
Sign up to set email alerts
|

Research Progress in Liver-Regenerating Microenvironment and DNA Methylation in Hepatocellular Carcinoma: The Role of Traditional Chinese Medicine

Abstract: The development, progression, recurrence, and metastasis of hepatocellular carcinoma (HCC) are closely associated with an abnormal liver-regenerating microenvironment (LRM). Therefore, preventing and reversing an abnormal LRM is a potential therapeutic strategy against HCC. Studies are increasingly focusing on the impact of regeneration, fibrosis, angiogenesis, inflammation, immunomodulation, and hepatic stem cells on HCC development and progression. As a key epigenetic mechanism, DNA methylation is extensivel… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
7
0

Year Published

2020
2020
2023
2023

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 10 publications
(7 citation statements)
references
References 90 publications
(87 reference statements)
0
7
0
Order By: Relevance
“…DNA methylation modifications are extensively involved in regulating physiological and pathological pathways in HCC [ 26 , 27 ]. We explored the DNA methylation status of the SPC25 gene in HCC using MEXPRESS.…”
Section: Resultsmentioning
confidence: 99%
“…DNA methylation modifications are extensively involved in regulating physiological and pathological pathways in HCC [ 26 , 27 ]. We explored the DNA methylation status of the SPC25 gene in HCC using MEXPRESS.…”
Section: Resultsmentioning
confidence: 99%
“…Hypermethylation of gene promoters has been demonstrated as an early event in hepatocellular carcinogenesis. 25 In this study, we quantified the circulating MP16 levels using Rt-PCR in patients with HCV-related CLD for screening and early detection of HCC. These levels were significantly higher in patients with HCC as compared to patients with BLD or normal controls.…”
Section: Discussionmentioning
confidence: 99%
“…The 1-year survival rate of PLC is only 38% [27]. CM has been employed to treat disease for a long time in Southeast Asia [28][29][30][31]. As for the aspects of limiting symptoms, reducing treatment associated side effects, inhibiting tumor growth and altering key intracellular signaling pathways, many studies have been proved that CM has advantages for patients with PLC [32][33][34].In this retrospective study, the overall survival of patients receiving CM therapy more than 6 months was prolonged.…”
Section: Discussionmentioning
confidence: 99%